Alector to Present at Three Healthcare Conferences in September 2025
ByAinvest
Friday, Aug 29, 2025 7:58 pm ET1min read
ALEC--
Alector's management will engage in fireside chats and company presentations at these events, with webcasts available for attendees and investors. The webcasts will be accessible on Alector's investor relations website for 90 days following each conference [1].
The company focuses on developing therapies to counteract the progression of neurodegenerative diseases such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Alector's proprietary Alector Brain Carrier (ABC) platform aims to enhance the delivery of therapeutics, achieve deeper brain penetration, and improve patient outcomes [1].
Alector's involvement in these conferences comes amidst positive developments in the biotech sector. Coya Therapeutics (NASDAQ: COYA), another biotech company focused on neurodegenerative diseases, has recently received a Buy rating from BTIG, with a $15.00 price target, citing positive clinical data for its COYA-302 therapy in ALS and FTD patients [2].
References:
[1] https://www.globenewswire.com/news-release/2025/08/28/3140717/0/en/Alector-to-Participate-in-Upcoming-Healthcare-Conferences.html
[2] https://www.investing.com/news/analyst-ratings/coya-therapeutics-stock-maintains-buy-rating-at-btig-on-positive-als-data-93CH-4208464
Alector, a late-stage clinical biotech company, will present at three healthcare investor conferences in September 2025. The company's presentations will be available via webcast on its investor relations website, with replays accessible for up to 90 days. Alector is focused on developing therapies for neurodegeneration, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, using its proprietary Alector Brain Carrier platform.
Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company specializing in neurodegenerative disease therapies, has announced its participation in three upcoming healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference 2025, Morgan Stanley 23rd Annual Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Investment Conference, all taking place in New York City.Alector's management will engage in fireside chats and company presentations at these events, with webcasts available for attendees and investors. The webcasts will be accessible on Alector's investor relations website for 90 days following each conference [1].
The company focuses on developing therapies to counteract the progression of neurodegenerative diseases such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Alector's proprietary Alector Brain Carrier (ABC) platform aims to enhance the delivery of therapeutics, achieve deeper brain penetration, and improve patient outcomes [1].
Alector's involvement in these conferences comes amidst positive developments in the biotech sector. Coya Therapeutics (NASDAQ: COYA), another biotech company focused on neurodegenerative diseases, has recently received a Buy rating from BTIG, with a $15.00 price target, citing positive clinical data for its COYA-302 therapy in ALS and FTD patients [2].
References:
[1] https://www.globenewswire.com/news-release/2025/08/28/3140717/0/en/Alector-to-Participate-in-Upcoming-Healthcare-Conferences.html
[2] https://www.investing.com/news/analyst-ratings/coya-therapeutics-stock-maintains-buy-rating-at-btig-on-positive-als-data-93CH-4208464
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet